Biomarkers like MR-proADM and CT-proAVP predict severity and outcome in critically ill COVID-19 patients. MR-proADM and CT-proAVP at admittance can be higher in non-survivors and biomarker clearance over the days will be higher in survivors.
Bron
Verkorte titel
Aandoening
Lower respiratory tract infections
Ondersteuning
Onderzoeksproduct en/of interventie
Geen registraties gevonden.
Uitkomstmaten
Primaire uitkomstmaten
28-day mortality
Achtergrond van het onderzoek
Background:
At this moment new Corona Virus Disease 2019 (COVID-19) patients will be hospitalised and admitted to the ICU. Little is known of prognostic factors predicting outcome. Which patients will survive and which patients have to stay longer at the ICU and on a ventilator? Can biomarkers like mid-regional proadrenomedullin (MR-proADM) and proarginin-vasopressin (CT-proAVP) at admittance or in serial measurements predict severity and outcome in critically ill COVID-19 patients?
Objective:
The aim of this prospective study is to elucidate whether biomarkers like MR-proADM and CT-proAVP could be used as a marker for severity and prognosis.
Study design:
A single center prospective observational study.
Study population:
SARS-CoV 2 PCR positive patients admitted to the ICU.
Intervention
Blood will drawn during routine daily laboratory rounds and stored at -80 degrees celcius until biomarkers will be assayed later.
The electronic patient database will be searched for survival after 28 and 90 days, LOS ICU and hospital and time on the ventilator.
Main outcome measurement
28-day mortality
Secondary outcome measurement
90-day mortality, length of stay (LOS) ICU and hospital, time on the ventilator.
Doel van het onderzoek
Biomarkers like MR-proADM and CT-proAVP predict severity and outcome in critically ill COVID-19 patients. MR-proADM and CT-proAVP at admittance can be higher in non-survivors and biomarker clearance over the days will be higher in survivors.
Onderzoeksopzet
28 days and 90 days after inclusion the electronic patient database will be searched for survival.
Onderzoeksproduct en/of interventie
During routine daily laboratory rounds blood will be stored at -80 C until biomarkers will be assayed later.
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
SARS-CoV 2 PCR positive patients at the intensive care
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
SARS-CoV 2 PCR negative OR no SARS-CoV 2 PCR
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiƫnten Data (IPD)
Toelichting
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL8460 |
Ander register | Wetenschapsbureau Elisabeth Tweesteden Ziekenhuis : L0977.2020 |